PERSPECTIVE THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $8.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2020-05-13.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2020-05-13
- PERSPECTIVE THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2019-03-31 was $8.00K.
- PERSPECTIVE THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2018-12-31 was $116.00K.
- PERSPECTIVE THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2012 was $61.51K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month as first filed |
|---|---|---|---|---|
| 2019-03-31 | $8.00K 10-Q · filed 2020-05-13 | $124.00K derived: sum of 2 quarters · filed 2020-05-13 | ||
| 2018-12-31 | $116.00K 10-Q · filed 2020-05-13 | |||
| 2012-06-30 | $61.51K 10-K · filed 2013-09-30 | -$61.51K 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |